Institutional Ownership
Evommune Inc
CUSIP 30054Y107COM SHSEVMNQ1 2026
13D / 13G Filings
6
Schedule 13D/13G on record
Beneficial Filers
4
Distinct reporting persons
Largest Stake
15.7%
Max % of class reported
Institutional Holders
79
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
6 filings · latest Feb 19, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 19, 2026 | Lsp 7 Cooperatieve U.A. | 13D/A | 14.7% | — | SEC |
| 2 | Feb 17, 2026 | Ra Capital Management, L.P. | 13D/A | 9.7% | — | SEC |
| 3 | Feb 13, 2026 | Nan Fung Group Holdings Limited | 13G | 10.9% | 3.44M | SEC |
| 4 | Nov 17, 2025 | Andera Partners | 13G | 6.0% | 1.90M | SEC |
| 5 | Nov 17, 2025 | Ra Capital Management, L.P. | 13D | 11.0% | — | SEC |
| 6 | Nov 14, 2025 | Lsp 7 Cooperatieve U.A. | 13D | 15.7% | — | SEC |
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Eqt Fund Management S.A R.L. | 4.93M | $113.33M |
| 2 | Ra Capital Management, L.P. | 3.49M | $80.34M |
| 3 | Pivotal Bioventure Partners Investment Advisor LLC | 1.93M | $44.30M |
| 4 | Andera Partners | 1.90M | $43.62M |
| 5 | Rtw Investments, LP | 1.50M | $34.54M |
| 6 | Mpm Bioimpact LLC | 1.46M | $33.47M |
| 7 | Nan Fung Group Holdings Ltd | 1.44M | $33.13M |
| 8 | Jpmorgan Chase & Co | 1.46M | $32.11M |
| 9 | Symbiosis Capital Partners, LLC | 1.28M | $29.45M |
| 10 | Eventide Asset Management, LLC | 1.21M | $27.80M |